Pfizer and UCB have formed a new technology company, Cyclofluidic, established with the goal of accelerating the drug discovery process by allowing researchers to test a broader range of potential new drug in less time. The UK Government’s Technology Strategy Board helped to facilitate this arrangement between the two companies and will continue to support Cyclofluidic by co-funding its R&D. The new company will be jointly owned by Pfizer and UCB.

Cyclofluidic’s goal is to develop technologies that automate and integrate processes known as flow chemistry and flow biology to help pharmaceutical companies shorten timelines within the drug development process. Through extensive collaboration with key academics and component manufacturers, Cyclofluidic plans to develop a microfluidic closed loop lead optimization platform that will enable researchers to access expertise in flow chemistry, flow screening and microfluidic engineering. Cyclofluidic will also provide training for both flow chemistry and biology scientists at its facility located in the South of England.

Iain Gray, chief executive officer of Technology Strategy Board, said, “Our role is to stimulate the development and deployment of technologies which, as well as benefiting society, also provide global business opportunities for the UK. Cyclofluidic is an excellent example of the private and public sectors working together to develop world-leading technologies which have the potential to bring enormous benefit to patients in the and around the world. We are delighted to offer our support and investment.”

“Cyclofluidic’s entry into the rapidly evolving microfluidic technology area has the potential to radically transform the medicinal chemistry and biology interface,” said Dr. Neil Weir, senior vice president of research at UCB. “It’s an exciting opportunity for UCB and Pfizer to collaborate and offers real potential for improved productivity, underlining our commitment to innovation for patients.”